Inactive Instrument

LYSOGENE

Equities

LYS

FR0013233475

Biotechnology & Medical Research

Lysogene Appoints David Schilansky to Its Board

December 07, 2016 at 07:00 am EST

Lysogene appointed David Schilansky to the board of directors, as a non-executive, independent member. Mr. Schilansky, currently Deputy CEO and Chief Operating Officer of DBV Technologies, has 20 years of leadership experience in the field of biotechnology and finance.

Latest news about LYSOGENE

Lysogene S.A.(ENXTPA:LYS) dropped from CAC AllShares Index	23-07-06	CI
Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index	23-07-06	CI
Lysogene CFO Assumes Same Role at Mauna Kea Technologies	23-06-14	MT
Lysogene: placed in liquidation and delisted	23-05-29	CF
Lysogene to Delist from Euronext amid Judicial Liquidation	23-05-29	MT
Lysogene S.A. Announces Postponement of 2022 Financial Results Release	23-04-29	CI
Lysogene: no takeover bid received for biotech company	23-04-17	CF
Lysogene Fails to Secure Takeover Bid Amid Reorganization	23-04-17	MT
Lysogene: deadline for takeover bids extended	23-03-27	CF
Lysogene: interim CFO confirmed	23-02-06	CF
French Gene Therapy Group Lysogene Makes Ad Interim CFO Permanent	23-02-06	MT
Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer	23-02-03	CI
Lysogene: company placed in receivership	23-01-25	CF
Lysogene: officially looking for a buyer	23-01-09	CF
Lysogene Seeks Launch of Safeguard Process Amid Financing Woes	22-12-07	MT
Lysogene Provides Updates and Topline Results from Phase 2/3 Aavance Gene Therapy Clinical Study	22-11-18	CI
Lysogene S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-23	CI
Lysogene Announces New Board of Directors	22-09-16	CI
Lysogene's Gene Therapy Improves Cognitive, Motor Functions In Initial Phase 2/3 Data	22-07-07	MT
Lysogene Provides Additional Update on Aavance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in Children with MMPS IIIA	22-07-07	CI
Lysogene S.A. Provides Clinical Update on AAvance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA At the 25Th Annual ASGCT Meeting	22-05-18	CI
Lysogene's Gene Therapy Shows Long-Term Rescue of Fragile X Syndrome in Mouse Model	22-04-21	MT
Lysogene S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of Mpsiiia	22-02-24	CI
Lysogene Reports Additional Positive Biomarker Data With LYS-SAF302 and Favorable Safety Data With LYS-GM101	22-02-11	CI

Chart LYSOGENE

Duration

Period

More charts

Company Profile

LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases. The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
EXACT SCIENCES CORPORATION	-27.45%	9.41B
IOVANCE BIOTHERAPEUTICS, INC.	+26.32%	2.9B
BGI GENOMICS CO., LTD.	-15.73%	2.16B
VERACYTE, INC.	-20.68%	1.7B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+67.48%	1.51B
CAREDX, INC	+26.96%	814M
SEEGENE, INC.	-4.15%	760M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-28.88%	529M
CURIOX BIOSYSTEMS CO., LTD	+3.98%	312M

Bio Diagnostics & Testing